Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 841 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR pCR Associated with Improved Survival Outcomes in Patients with Soft Tissue... April 3, 2023 FDA Approves Pembrolizumab as Adjuvant Treatment for NSCLC February 2, 2023 Maintenance Olaparib in Elderly Patients With a Germline BRCA Mutation and... July 1, 2020 Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities March 6, 2026 Load more HOT NEWS Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide... Brothers Break Down After Seeing Their Parents For First Time In... OncoArray Links Dozens of DNA Variants to Risk for Common Cancers After A Long And Dangerous Battle, Africa Has Been Declared Free...
